List of Excipients in Branded Drug BONJESTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Duchesnay USA Inc	BONJESTA	doxylamine succinate and pyridoxine hydrochloride	55494-120	ALCOHOL
Duchesnay USA Inc	BONJESTA	doxylamine succinate and pyridoxine hydrochloride	55494-120	AMMONIA
Duchesnay USA Inc	BONJESTA	doxylamine succinate and pyridoxine hydrochloride	55494-120	BUTYL ALCOHOL
Duchesnay USA Inc	BONJESTA	doxylamine succinate and pyridoxine hydrochloride	55494-120	CARNAUBA WAX
Duchesnay USA Inc	BONJESTA	doxylamine succinate and pyridoxine hydrochloride	55494-120	CELLULOSE, MICROCRYSTALLINE
Duchesnay USA Inc	BONJESTA	doxylamine succinate and pyridoxine hydrochloride	55494-120	CROSCARMELLOSE SODIUM
Duchesnay USA Inc	BONJESTA	doxylamine succinate and pyridoxine hydrochloride	55494-120	D&C RED NO. 27

Bonjesta Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Bonjesta is an oral extended-release combination of doxylamine succinate and pyridoxine hydrochloride for nausea and vomiting of pregnancy. Its commercial differentiation depends on controlled release, tablet manufacturability, tolerability, and reliable dosing rather than novel active ingredients. The main excipient opportunity is to improve release control, reduce tablet burden, support patient populations with dietary sensitivities, and create differentiated generic or follow-on products without changing the approved therapeutic concept.

Bonjesta is marketed by Duchesnay USA and was approved by the U.S. Food and Drug Administration in 2016 under NDA 208725. Each tablet contains 20 mg doxylamine succinate and 20 mg pyridoxine hydrochloride in a delayed-release dosage form. The product is taken on a scheduled basis rather than solely as needed, which makes formulation consistency commercially important. [1]

What excipients are used in Bonjesta?

Bonjesta uses a conventional oral solid dosage excipient system that supports tablet compression, coating, delayed release, and physical stability.

Bonjesta inactive ingredients

The FDA-approved labeling identifies the following inactive ingredients:

Excipient	Likely formulation function
Colloidal silicon dioxide	Glidant and flow aid
Croscarmellose sodium	Disintegrant
Hypromellose	Film former and release-control polymer
Lactose monohydrate	Diluent and bulking agent
Magnesium stearate	Lubricant
Microcrystalline cellulose	Filler, binder, and compression aid
Polyethylene glycol	Coating plasticizer
Polyvinyl alcohol	Film-coating polymer
Talc	Anti-tacking and coating aid
Titanium dioxide	Opacifier and colorant

The label describes Bonjesta as a pink, round, film-coated, extended-release tablet. [1] The excipient system is consistent with a compressed tablet containing a release-controlling matrix or barrier combined with a protective film coat.

The commercial value of this system is functional rather than ingredient-specific. Most listed excipients are established pharmaceutical ingredients with broad prior use. The defensible product characteristics are more likely to arise from the combination of active ingredients, dosage strengths, tablet architecture, manufacturing parameters, and release profile.

How does Bonjesta’s release system create commercial value?

Bonjesta’s principal formulation advantage is scheduled delivery from a solid oral dosage form. Doxylamine and pyridoxine are administered together, with the delayed-release profile intended to support symptom control over time.

Three formulation attributes have direct commercial relevance:

1. Release timing. The formulation must delay drug release sufficiently to produce the intended pharmacokinetic profile.
2. Dose uniformity. Each tablet must deliver consistent amounts of both active ingredients.
3. Physical robustness. The tablet must withstand compression, coating, packaging, storage, and patient handling without unacceptable changes in dissolution.

The excipient strategy can be optimized around these attributes. Hypromellose, polyvinyl alcohol, polyethylene glycol, and coating-process controls are central to release behavior and tablet protection. Microcrystalline cellulose and lactose influence tablet hardness, friability, compression force, and manufacturing throughput. Magnesium stearate and colloidal silicon dioxide affect powder flow and lubrication, but excessive lubrication or poor blending can alter tablet strength and dissolution.

A manufacturer seeking to develop an equivalent product would need to match the relevant pharmaceutical performance, not merely duplicate the ingredient list. Changes in polymer viscosity grade, particle size, coating weight, lubricant concentration, or compression force can change dissolution results.

What excipient changes could improve Bonjesta or create follow-on products?

The strongest commercial opportunities are incremental. They include excipient substitutions that address tolerability, manufacturing efficiency, or patient access while maintaining the intended release profile.

Lactose-free or low-lactose formulations

Lactose monohydrate is a common diluent, but a lactose-free formulation could target patients with lactose intolerance or improve suitability for selected markets. Replacement candidates include:

• Mannitol
• Dibasic calcium phosphate
• Spray-dried sucrose
• Additional microcrystalline cellulose
• Coprocessed cellulose-based excipients

A lactose-free product would require comparative dissolution, stability, tablet-strength, and bioequivalence work. The commercial value would depend on whether the product obtains a clear labeling distinction or captures institutional and pharmacy demand.

Reduced-magnesium-stearate formulations

Magnesium stearate is widely used, but its concentration and blending time can affect dissolution and tablet tensile strength. A formulation using lower lubricant levels or an alternative lubricant could improve process control. Candidates may include sodium stearyl fumarate or stearic acid, although each creates new compatibility and performance questions.

This strategy is more relevant to manufacturing efficiency than to direct patient differentiation. It could reduce batch variability if the existing process is sensitive to lubrication conditions.

Polymer and coating optimization

Hypromellose and polyvinyl alcohol provide multiple paths for formulation development:

• Different hypromellose viscosity grades
• Lower or higher polymer loading
• Multilayer tablet structures
• Modified film-coat weight
• Alternative enteric or delayed-release polymers
• Combination of matrix and barrier-coat approaches

These changes could support smaller tablets, altered dosing schedules, or more consistent release across fed and fasted conditions. They also create the strongest potential for formulation patents because patentability may arise from defined compositions, process conditions, dissolution windows, or pharmacokinetic outcomes.

Colorant and coating simplification

Titanium dioxide and talc are established coating materials, but some jurisdictions and customers have moved toward simplified or colorant-free formulations. A white, uncolored, or reduced-pigment tablet could lower regulatory complexity in certain markets and support a clean-label commercial position.

This opportunity is unlikely to justify a major U.S. product switch by itself. It could matter in international markets where excipient restrictions, consumer preferences, or local labeling requirements differ.

What patents protect Bonjesta and its formulation?

Bonjesta is a small-molecule product. Doxylamine succinate and pyridoxine hydrochloride are longstanding active ingredients, so the commercial protection does not depend on composition-of-matter exclusivity for a new chemical entity.

The relevant protection categories are:

Protection category	Relevance to Bonjesta
Active-ingredient patents	Limited because the ingredients are old
Combination patents	May cover the use of doxylamine and pyridoxine together
Method-of-use patents	May cover treatment of nausea and vomiting of pregnancy
Formulation patents	May cover delayed-release composition, tablet structure, or dissolution
Manufacturing patents	May cover coating, blending, compression, or release-control processes
Regulatory exclusivity	Applies separately from patent rights and depends on FDA designation

The Orange Book is the controlling public source for patents submitted for an approved prescription product. Current Bonjesta patent listings, expiration dates, and use codes must be evaluated from the FDA Orange Book record associated with NDA 208725 rather than inferred from older Diclegis records. [2]

Bonjesta and Diclegis are related products but are not interchangeable for patent analysis. Diclegis contains 10 mg doxylamine succinate and 10 mg pyridoxine hydrochloride per delayed-release tablet, while Bonjesta contains 20 mg of each active ingredient per tablet. [1,3] A patent covering the lower-strength product may not automatically block a Bonjesta-specific product, and a patent covering a particular strength or dosing regimen may not cover every generic strategy.

When does Bonjesta lose exclusivity?

Bonjesta’s active ingredients do not have meaningful new chemical entity protection. The relevant loss-of-exclusivity date depends on the latest enforceable patent and any FDA regulatory exclusivity associated with the NDA.

For commercial planning, the timeline should be analyzed in four layers:

Layer	Business question
FDA approval	When did NDA 208725 receive approval?
Orange Book patents	Which patents and use codes are listed for Bonjesta?
Patent term	When does each listed patent expire, including any adjustments or extensions?
Generic pathway	Can an ANDA applicant use Paragraph IV, a Section VIII statement, or a different route?

The 2016 approval date does not itself establish the generic entry date. A generic applicant can file an ANDA before patent expiration and challenge listed patents through a Paragraph IV certification. The timing of litigation, a 30-month stay, settlement terms, pediatric extensions, and any court decision can alter the practical entry date. [2,4]

What Paragraph IV challenges could affect Bonjesta?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. If the brand company files an infringement action within the statutory period after receiving notice, FDA approval may be delayed by a 30-month stay, subject to statutory exceptions and court outcomes. [4]

Potential generic strategies include:

• A product with the same active ingredients and comparable delayed-release performance
• A challenge to formulation-patent validity
• A non-infringing formulation using different polymers or coating parameters
• A Section VIII carve-out for a patented method of use
• A product relying on a different strength or dosing presentation

For Bonjesta, formulation and method-of-use claims are more commercially relevant than active-ingredient claims. A successful Paragraph IV challenger could enter before the last listed patent expires, but litigation risk would depend on claim scope, prosecution history, infringement testing, and the proposed generic’s dissolution and manufacturing profile.

No biosimilar pathway applies. Bonjesta is a conventional small-molecule drug, and follow-on products would generally use the ANDA pathway rather than a biosimilar application under the Public Health Service Act.

What FDA regulatory status applies to Bonjesta generics?

A generic Bonjesta-type product would generally require an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. The applicant would need to address:

• Same active ingredients
• Same dosage form
• Same route of administration
• Same strength
• Comparable release characteristics
• Bioequivalence under FDA requirements
• Appropriate labeling and inactive-ingredient controls

Modified-release products can be more difficult than immediate-release tablets because the applicant must control dissolution across multiple test conditions and demonstrate that formulation changes do not create clinically meaningful exposure differences.

An excipient substitution may be acceptable if it does not affect safety, efficacy, bioequivalence, or product performance. Excipients with known hypersensitivity, gastrointestinal tolerability, or route-specific concerns require particular attention in the ANDA review.

How strong is the Bonjesta patent estate?

The estate is structurally stronger around formulation and use than around the active ingredients. Its strength depends on the breadth and remaining term of listed claims.

Factor	Assessment
Active-ingredient protection	Weak because the ingredients are established
Combination protection	Potentially meaningful if claim scope is broad
Delayed-release formulation	Commercially important and potentially defensible
Method of use	Relevant to pregnancy-related nausea and vomiting
Manufacturing claims	Usually narrower but can complicate design-around efforts
Biosimilar barrier	Not applicable
Generic substitution risk	Material once enforceable formulation and use barriers expire

A narrow formulation patent may still delay a generic if the generic cannot establish a reliable non-infringing design without compromising bioequivalence. Conversely, a generic that uses a different polymer system, coating process, or dosing design may reduce infringement exposure.

Which companies could challenge Bonjesta?

The likely challengers are established generic manufacturers with modified-release tablet capabilities. Potential participants in this market include large ANDA filers and contract development and manufacturing organizations with expertise in controlled-release oral solids.

The strongest candidates would have:

• Experience with delayed-release tablets
• Access to bioequivalence and dissolution testing
• Manufacturing capacity for small-volume specialty products
• Patent litigation resources
• Commercial relationships with U.S. wholesalers and pharmacies

Market entry could occur through a direct ANDA, a licensing arrangement, or a private-label product supplied by a generic manufacturer. The product’s pregnancy indication may support stable demand, but the market is narrower than for high-volume chronic medicines.

What licensing and commercial opportunities exist?

The most attractive opportunities are formulation and geographic licensing rather than active-ingredient licensing.

Formulation licensing

A company with a lactose-free, smaller, more stable, or lower-cost delayed-release tablet could license the technology to a generic manufacturer or specialty pharmaceutical company. The licensor could provide:

• Formulation composition
• Coating and process parameters
• Dissolution specifications
• Stability data
• Scale-up support
• Patent rights or know-how

Geographic licensing

Bonjesta’s commercial model can vary by jurisdiction because pregnancy-related nausea and vomiting is treated under different prescribing and reimbursement systems. Licensing opportunities may exist where:

• The product is not marketed under the Bonjesta brand
• A local company has regulatory access
• Local excipient rules favor a reformulated product
• The product can be supplied under a different strength or dosing schedule

Patient-segment products

Potential differentiated products include:

• Lactose-free tablets
• Colorant-reduced tablets
• Lower-tablet-burden regimens
• Unit-dose blister packaging
• Pharmacy-dispensed starter packs
• Products optimized for swallowing difficulty

The strongest commercial case would combine a meaningful patient benefit with a patentable formulation or a regulatory pathway that is manageable relative to expected market size.

What manufacturing and IP barriers limit competition?

The main manufacturing barrier is reproducible delayed release at commercial scale. Small changes in blend uniformity, coating weight, polymer grade, tablet hardness, or storage humidity can affect dissolution.

The main IP barrier is the interaction between formulation design and patent claims. A generic manufacturer may avoid a literal formulation claim but still face infringement risk if its process or release profile falls within a method or composition claim.

Critical development controls include:

• Active-ingredient segregation prevention
• Uniform distribution of low-dose pyridoxine and doxylamine
• Coating thickness control
• Moisture protection
• Dissolution testing in multiple media
• Stability under accelerated and long-term conditions
• Packaging that limits humidity exposure

The best design-around strategy is usually a deliberate alternative formulation developed early, not a late substitution after the reference composition has been copied.

How does Bonjesta compare with Diclegis?

Attribute	Bonjesta	Diclegis
Active ingredients	Doxylamine succinate and pyridoxine HCl	Doxylamine succinate and pyridoxine HCl
Strength per tablet	20 mg/20 mg	10 mg/10 mg
Dosage form	Delayed-release tablet	Delayed-release tablet
Primary commercial distinction	Higher strength and lower tablet burden	Established lower-strength product
Patent analysis	Bonjesta-specific listings and claims	Separate NDA and patent record
Generic pathway	ANDA, subject to listed patents and bioequivalence	ANDA, subject to separate listed patents and bioequivalence

The products should be analyzed separately for Orange Book listings, patent scope, labeling, and bioequivalence. A product that is equivalent to Diclegis is not automatically equivalent to Bonjesta.

Key Takeaways

• Bonjesta’s commercial differentiation is based on delayed release, combination dosing, and tablet performance.
• The principal excipients are hypromellose, polyvinyl alcohol, polyethylene glycol, lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, talc, titanium dioxide, and colloidal silicon dioxide.
• The most credible product opportunities are lactose-free formulations, simplified coatings, smaller tablets, improved packaging, and manufacturing-process improvements.
• Patent value is concentrated in formulation, method-of-use, and manufacturing claims rather than active-ingredient patents.
• Bonjesta is a small-molecule product, so biosimilar competition does not apply.
• Generic competition would generally proceed through the ANDA pathway, with Paragraph IV and Section VIII strategies depending on listed patents and use codes.
• Bonjesta and Diclegis require separate patent, regulatory, and bioequivalence analyses.
• A differentiated excipient strategy is most valuable when it produces measurable dissolution, tolerability, stability, or tablet-size advantages.

FAQs

Can lactose be removed from Bonjesta without changing the product’s regulatory status?

A lactose-free version would be a new formulation requiring formulation development and regulatory support. The change would need to preserve release performance, stability, and bioequivalence where applicable.

Is a Bonjesta generic required to use the same excipients?

No. An ANDA applicant generally may use different inactive ingredients if the product remains pharmaceutically equivalent, bioequivalent, stable, and acceptable under FDA requirements.

Can a generic Bonjesta use a different delayed-release polymer?

Yes, if the alternative polymer system produces the required release profile and supports approval. The applicant must also evaluate patent infringement and demonstrate that the product meets applicable bioequivalence requirements.

Does Bonjesta qualify for biosimilar competition?

No. Bonjesta is a small-molecule oral tablet. Follow-on products would generally use the ANDA pathway rather than the biosimilar pathway.

Is Bonjesta interchangeable with Diclegis?

Not automatically. The products contain the same active ingredients but differ in strength and may have separate FDA records, labeling, patent listings, and substitution requirements.

References

1. U.S. Food and Drug Administration. (2023). Bonjesta (doxylamine succinate and pyridoxine hydrochloride) extended-release tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. U.S. Food and Drug Administration. (2013). Diclegis (doxylamine succinate and pyridoxine hydrochloride) delayed-release tablets: Prescribing information.
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application.